Sintilimab is a highly selective fully human IgG4 monoclonal antibody against PD-1, that promotes the restoration of endogenous anti-tumor T cell responses by blocking the interaction between PD-1 and its ligands (PD-L1/2)20. The gene discussed is CD274; the disease is neoplasm.